Boston Scientific (BSX)
(Delayed Data from NYSE)
$86.70 USD
+0.86 (1.00%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $86.71 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
BSX 86.70 +0.86(1.00%)
Will BSX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BSX
MDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?
CAH Stock May Gain Following the Distribution Deal With T2 Biosystems
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Integer Holdings (ITGR) Gains 30.5% YTD: What's Driving the Stock?
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?
Other News for BSX
Axonics gains after Boston Scientific says it will end use of Coaptite on Nov. 1
Boston Scientific price target raised by $10 at RBC Capital, here's why
Boston Scientific (BSX) Gets a Buy from Bank of America Securities
Blackstone Minerals Announces Option Cessations
Uptrend Resumption Likely For Earnings